C
331920
vs
K
KOSPI 200
Over the past 12 months, Celemics Inc has outperformed KOSPI 200, delivering a return of +190% compared to KOSPI 200's +153% growth.
Stocks Performance
331920 vs KOSPI 200
Performance Gap
331920 vs KOSPI 200
Performance By Year
331920 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Celemics Inc
Glance View
Celemics makes DNA testing tools for laboratories that work with next-generation sequencing. Its main products are target-enrichment kits, custom probe panels, and related sample-preparation reagents that help labs pull out the exact genetic regions they want to read before sequencing. In simple terms, it sells the “prep work” that makes sequencing more accurate and efficient. Its customers are research labs, clinical testing labs, hospitals, and biotech companies that need to study genes for cancer, inherited disease, infectious disease, and other applications. Celemics earns money by selling these kits and custom-designed products, often tailored to a customer’s specific testing panel or research need. That makes it more of a specialized supplier than a broad consumer-facing drug or diagnostics company. What sets the business apart is that it sits upstream in the genomics workflow. Instead of running the tests itself, it provides the consumable reagents and custom design work that other labs use to do sequencing. That gives Celemics a role similar to a picks-and-shovels supplier in the genetics industry, where demand depends on how much sequencing and genetic testing customers want to perform.
